Literature DB >> 3132589

High cholesterol levels: is mass screening the best option?

S Kinlay1.   

Abstract

Individuals with a high cholesterol level (greater than 6.5 mmol/L) are at a relatively high risk of developing coronary heart disease in the future and an important part of any programme to prevent coronary heart disease is the identification and treatment of these individuals. Mass screening can identify those who are at an increased risk but the likely benefits and costs of such a programme have not been assessed adequately. Before such a method is promoted, we need to know: how well it detects high-risk individuals (yield); what reductions in the risk of coronary heart disease can be expected in those who are screened as "positive"; what adverse effects screening may have on those who are screened as "negative"; and what the logistics and costs (both to those who are screened and to the community as a whole) are. Until we know this information the urge to promote mass screening for cholesterol levels should be restrained, and only those who are at high risk of coronary heart disease should be selected for the determination of their cholesterol levels.

Entities:  

Mesh:

Year:  1988        PMID: 3132589     DOI: 10.5694/j.1326-5377.1988.tb116339.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  3 in total

Review 1.  Who should have their cholesterol concentration measured? What experts in the United Kingdom suggest.

Authors:  D Leitch
Journal:  BMJ       Date:  1989-06-17

2.  Selective screening for high cholesterol in Australian general practice: the Newcastle Cholesterol Prediction Study.

Authors:  S Kinlay; R F Heller
Journal:  J Gen Intern Med       Date:  1990 Jan-Feb       Impact factor: 5.128

3.  "Couldn't you have done just as well without the screening?". A qualitative study of benefits from screening as perceived by people without a high cardiovascular risk score.

Authors:  Karen-Dorthe Bach Nielsen; Lise Dyhr; Torsten Lauritzen; Kirsti Malterud
Journal:  Scand J Prim Health Care       Date:  2009       Impact factor: 2.581

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.